Abdel-Fatah TM - Search Results

1

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. Hickey TE, et al. Among authors: abdel fatah tm. Nat Med. 2021 Feb;27(2):310-320. doi: 10.1038/s41591-020-01168-7. Epub 2021 Jan 18. Nat Med. 2021. PMID: 33462444

2

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.

Habashy HO, Powe DG, Abdel-Fatah TM, Gee JM, Nicholson RI, Green AR, Rakha EA, Ellis IO. Habashy HO, et al. Histopathology. 2012 May;60(6):854-63. doi: 10.1111/j.1365-2559.2011.03912.x. Epub 2011 Sep 10. Histopathology. 2012. PMID: 21906125 Review.

3

SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.

Zwart W, Flach KD, Rudraraju B, Abdel-Fatah TM, Gojis O, Canisius S, Moore D, Nevedomskaya E, Opdam M, Droog M, Hofland I, Chan S, Shaw J, Ellis IO, Coombes RC, Carroll JS, Ali S, Palmieri C. Zwart W, et al. Clin Cancer Res. 2016 Jan 15;22(2):479-91. doi: 10.1158/1078-0432.CCR-14-3277. Epub 2015 Sep 14. Clin Cancer Res. 2016. PMID: 26369632

4

Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer.

Abdel-Fatah TM, Perry C, Moseley P, Johnson K, Arora A, Chan S, Ellis IO, Madhusudan S. Abdel-Fatah TM, et al. Breast Cancer Res Treat. 2014 Feb;143(3):411-21. doi: 10.1007/s10549-013-2820-7. Epub 2014 Jan 1. Breast Cancer Res Treat. 2014. PMID: 24381055

5

Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.

Abdel-Fatah TMA, Ball GR, Thangavelu PU, Reid LE, McCart Reed AE, Saunus JM, Duijf PHG, Simpson PT, Lakhani SR, Pongor L, Gyorffy B, Moseley PM, Green AR, Pockley AG, Caldas C, Ellis IO, Chan SYT. Abdel-Fatah TMA, et al. JAMA Netw Open. 2020 Jul 1;3(7):e209486. doi: 10.1001/jamanetworkopen.2020.9486. JAMA Netw Open. 2020. PMID: 32633764 Free PMC article.

6

Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.

Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO. Abdel-Fatah TM, et al. Am J Surg Pathol. 2008 Apr;32(4):513-23. doi: 10.1097/PAS.0b013e318161d1a5. Am J Surg Pathol. 2008. PMID: 18223478

7

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Green AR, Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO. Green AR, et al. Breast Cancer Res Treat. 2014 May;145(1):33-44. doi: 10.1007/s10549-014-2925-7. Epub 2014 Apr 6. Breast Cancer Res Treat. 2014. PMID: 24706169 Free PMC article.

8

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C. Rudraraju B, et al. Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22. Breast Cancer Res Treat. 2014. PMID: 25141981

9

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY. Abdel-Fatah TM, et al. Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168. Epub 2014 Apr 22. Br J Cancer. 2014. PMID: 24755885 Free PMC article.

10

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.

Powe DG, Akhtar G, Habashy HO, Abdel-Fatah T, Rakha EA, Green AR, Ellis IO. Powe DG, et al. Breast Cancer Res. 2009;11(6):R90. doi: 10.1186/bcr2461. Epub 2009 Dec 21. Breast Cancer Res. 2009. PMID: 20025767 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page